Trial reportEuropean heart journal2018
Blood pressure, heart rate, and mortality in chronic obstructive pulmonary disease: the SUMMIT trial.
Trial report in European heart journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 48 citations in OpenAlex.
- Absence of Adverse Effects of Tiotropium/Olodaterol Compared with the Monocomponents on Long-Term Heart Rate and Blood Pressure in Patients with Moderate-to-Very-Severe COPD.International journal of chronic obstructive pulmonary disease · 2020Trial
- Validation of the Summit Lab Score in Predicting Exacerbations of Chronic Obstructive Pulmonary Disease Among Individuals with High Arterial Stiffness.International journal of chronic obstructive pulmonary diseaseTrial
- Association between statins and chronic obstructive pulmonary disease: insights from cohort and genetic validation.Journal of thoracic disease · 2026Article
- Development and internal validation of a nomogram for predicting in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease.Journal of thoracic disease · 2026Article
- Mapping the Comorbidome in Chronic Obstructive Pulmonary Disease: Prevalence and Mortality Risk in a Colombian Cohort.Journal of clinical medicine · 2026Article
- COPD airway epithelial cells-derived extracellular vesicles contribute to endothelial dysfunction and atherosclerosis via the miR-141-3p/PDCD4 axis.Journal of nanobiotechnology · 2026Article
- Comparing the predictive accuracy of life's essential 8 and life's crucial 9 scores for all-cause mortality in COPD patients among US adults: a prospective cohort study.BMC public health · 2026Article
- Tailored Exercise Prescription for People with COPD and Clinically Relevant Comorbidities: A Consensus Statement of the EXPERT Working Group and Experts in Pulmonary Rehabilitation.Sports medicine (Auckland, N.Z.) · 2026Review
- Prolonged elevated heart rate and 28-day mortality in acute exacerbations of chronic obstructive pulmonary disease patients insights from the MIMIC-IV database.Scientific reports · 2025Article
- Inflammatory Markers Mediate the Association Between Cardiovascular Health and Chronic Inflammatory Airway Diseases: A Cross-Sectional Study on the Population Aged 50 Years and Above From NHANES 2013-2018.Mediators of inflammation · 2025Article
- Association of lifestyle factors with mortality risk in people with chronic obstructive pulmonary disease: a prospective cohort study.Frontiers in medicine · 2025Article
- Association between admission heart rate and in-hospital mortality in patients with acute exacerbation of chronic obstructive pulmonary disease and respiratory failure: a retrospective cohort study.BMC pulmonary medicine · 2024Article
- A simple clinical risk score (ABCDMP) for predicting mortality in patients with AECOPD and cardiovascular diseases.Respiratory research · 2024Article
- Development and Validation of an In-Hospital Mortality Prediction Model for Patients with Acute Exacerbation of Chronic Obstructive Pulmonary Disease.International journal of chronic obstructive pulmonary disease · 2024Article
- Systolic blood pressure, chronic obstructive pulmonary disease and cardiovascular risk.Heart (British Cardiac Society) · 2023Article
- Elevated BUN Upon Admission as a Predictor of in-Hospital Mortality Among Patients with Acute Exacerbation of COPD: A Secondary Analysis of Multicenter Cohort Study.International journal of chronic obstructive pulmonary disease · 2023Article
- COPD mortality and exacerbations in the placebo group of clinical trials over two decades: a systematic review and meta-regression.ERJ open research · 2022Review
- Prognostic value of blood pressure and resting heart rate in patients with tricuspid regurgitation.Frontiers in cardiovascular medicine · 2022Article
- To Dip or not to Dip Blood Pressure in Chronic Obstructive Pulmonary Disease: That is the Question!Arquivos brasileiros de cardiologia · 2021Article
- Nocturnal Heart Rate and Cardiac Repolarization in Lowlanders With Chronic Obstructive Pulmonary Disease at High Altitude: Data From a Randomized, Placebo-Controlled Trial of Nocturnal Oxygen Therapy.Frontiers in medicine · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 8 institutions in 2 countries.
Funding
Abstract
Aims: To characterize the relationship between blood pressure (BP) or heart rate and mortality and morbidity in chronic obstructive pulmonary disease (COPD). Methods and results: We performed post hoc analysis of baseline BP or heart rate and all-cause mortality and cardiovascular events in the SUMMIT trial. SUMMIT was a randomized double-blind outcome trial of 16 485 participants (65 ± 8 years, 75% male, and 47% active smokers) enrolled at 1368 sites in 43 countries. Participants with moderate COPD with or at risk for cardiovascular disease (CVD) were randomized to placebo, long-acting beta agonist, inhaled corticosteroid, or their combination. All-cause mortality increased in relation to high systolic [≥140 mmHg; hazard ratio (HR) 1.27, 95% confidence interval (CI) 1.12-1.45] or diastolic (≥90 mmHg; HR 1.35, 95% CI 1.14-1.59) BP and low systolic (<120 mmHg; HR 1.36, 95% CI 1.13-1.63) or diastolic (<80 mmHg; HR 1.15, 95% CI 1.00-1.32) BP. Higher heart rates (≥80 per minute; HR 1.39, 95% CI 1.21-1.60) and pulse pressures (≥80 mmHg; HR 1.39, 95% CI 1.07-1.80) were more linearly related to increases in all-cause mortality. The risks of cardiovascular events followed similar patterns to all-cause mortality. Similar findings were observed in subgroups of patients without established CVD. Conclusion: A 'U-shaped' relationship between BP and all-cause mortality and cardiovascular events exists in patients with COPD and heightened cardiovascular risk. A linear relationship exists between heart rate and all-cause mortality and cardiovascular events in this population. These findings extend the prognostic importance of BP to this growing group of patients and raise concerns that both high and low BP may pose health risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.